ClinicalTrials.gg

Program

bempedoic acid

Also written as “ETC-1002”, “Bempedoic acid” and “180mg of ETC-1002(bempedoic acid)”.

Its studies are mostly in Hypercholesterolemia · Hyperlipidemias · Dyslipidemias · Coronary Artery Disease · Hyperlipoproteinemia Type II, led by 6 companies.

Furthest: phase 4, since Aug 27, 202333 company-led studies, 2 open or runningNext primary completion: Jun 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Esperion Therapeutics200 open or runningphase 4since Aug 27, 2023Dec 16, 2010none ahead
Daiichi Sankyo61 open or runningphase 4since Apr 6, 2025Apr 6, 2025Jun 1, 2028phase 3 · NCT07474649
Otsuka30 open or runningphase 3since Jan 4, 2023Mar 2, 2021none ahead
Humanis Saglık Anonim Sirketi20 open or runningphase 1since Apr 4, 2025Apr 4, 2025none ahead
CSPC Pharmaceutical Group11 open or runningphase 3since May 29, 2026May 29, 2026Jun 30, 2027phase 3 · NCT07623915
Gan & Lee Pharmaceuticals10 open or runningphase 3since Jan 13, 2025Jan 13, 2025none ahead

Also a collaborator on its studies: medpace-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 16 studies since Dec 16, 2010.

  1. Jun 19, 2017Phase 2 study in HypercholesterolemiaEsperion Therapeutics · NCT03193047 · 59 enrolled · United States
  2. Nov 6, 2017Phase 3 study in HyperlipidemiasEsperion Therapeutics · NCT03337308 · 382 enrolled · United States
  3. Mar 2, 2021Otsuka's first study: phase 2 study in HypercholesterolemiaNew to OtsukaOtsuka · NCT04784442 · 188 enrolled · Japan
  4. Jan 4, 20232 phase 3 studies in Hyper-low-density Lipoprotein (LDL) CholesterolemiaOtsuka · NCT05687071, NCT05683340
  5. Jan 12, 2023Phase 2 study in HypercholesterolemiaEsperion Therapeutics · NCT05694260 · 31 enrolled · United States, Canada, Denmark and more
  6. Aug 27, 2023Phase 4 study in Healthy Lactating WomenEsperion Therapeutics · NCT06021951 · 16 enrolled · United States
  7. Jan 13, 2025Gan & Lee Pharmaceuticals's first study: phase 3 study in HyperlipidemiasNew to Gan & Lee PharmaceuticalsGan & Lee Pharmaceuticals · NCT06780410 · 245 enrolled · China
  8. Apr 4, 2025Humanis Saglık Anonim Sirketi's first study: phase 1 study in HypercholesterolemiaNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT06923956 · 14 enrolled · India
  9. Apr 6, 2025Daiichi Sankyo's first study: phase 4 study in Hyperlipoproteinemia Type IINew to Daiichi SankyoDaiichi Sankyo · NCT06925100 · 180 enrolled · Taiwan
  10. Sep 5, 2025Phase 1 study in HypercholesterolemiaHumanis Saglık Anonim Sirketi · NCT07170852 · 32 enrolled · India
  11. Sep 11, 20252 phase 1 studies in Healthy SubjectsDaiichi Sankyo · NCT07182383, NCT07201545
  12. Nov 14, 20252 phase 1 studies in Healthy SubjectsDaiichi Sankyo · NCT07235189, NCT07268625
  13. Mar 11, 2026Phase 3 study in Coronary Artery DiseaseDaiichi Sankyo · NCT07474649 · 103 planned · Germany, Italy, Spain
  14. May 29, 2026CSPC Pharmaceutical Group's first study: phase 3 study in Primary HyperlipidemiaNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT07623915 · 222 planned

Ahead

  1. Jun 30, 2027Primary completion: phase 3 study in Primary HyperlipidemiaCSPC Pharmaceutical Group · NCT07623915
  2. Jun 1, 2028Primary completion: phase 3 study in Coronary Artery DiseaseDaiichi Sankyo · NCT07474649

TargetBeta

ACLY →read by rule
“An orally bioavailable prodrug and inhibitor of adenosine triphosphate-citrate lyase (ACL), with anti-hyperlipidemic activity”NCIt, by rule
“ATP-citrate synthase inhibitor”ChEMBL 37, by rule

Studies

All 33 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07623915Primary Hyperlipidemia3Not yet recruitingCSPC Pharmaceutical GroupJun 30, 2027222
NCT07474649Coronary Artery Disease · Germany, Italy, Spain3Not yet recruitingDaiichi SankyoJun 1, 2028103
NCT07268625Healthy Subjects · Portugal1CompletedDaiichi SankyoFeb 24, 202658
NCT07235189Healthy Subjects · Portugal1CompletedDaiichi SankyoJan 28, 202658
NCT07201545Healthy Subjects · Portugal1CompletedDaiichi SankyoDec 10, 202558
NCT07182383Healthy Subjects · Portugal1CompletedDaiichi SankyoNov 24, 202558
NCT07170852Hypercholesterolemia · India1CompletedHumanis Saglık Anonim SirketiJun 16, 202532
NCT06925100Hyperlipoproteinemia Type II · Taiwan4CompletedDaiichi SankyoOct 15, 2025180
NCT06923956Hypercholesterolemia · India1CompletedHumanis Saglık Anonim SirketiDec 18, 202414
NCT06780410Hyperlipidemias · China3CompletedGan & Lee PharmaceuticalsAug 5, 2025245
NCT06021951Healthy Lactating Women · United States4CompletedEsperion TherapeuticsFeb 21, 202416
NCT05694260Hypercholesterolemia · United States, Canada, Denmark and more2CompletedEsperion TherapeuticsJun 4, 202531
NCT05687071Hyper-low-density Lipoprotein (LDL) Cholesterolemia · Japan3CompletedOtsukaOct 5, 2024130
NCT05683340Hyper-low-density Lipoprotein (LDL) Cholesterolemia · Japan3CompletedOtsukaFeb 20, 202496
NCT04784442Hypercholesterolemia · Japan2CompletedOtsukaApr 18, 2022188
NCT03337308Hyperlipidemias · United States3CompletedEsperion TherapeuticsJun 18, 2018382
NCT03193047Hypercholesterolemia · United States2CompletedEsperion TherapeuticsJan 29, 201859
NCT03067441Hypercholesterolemia · United States3CompletedEsperion TherapeuticsNov 5, 20191,462
NCT03051100Hypercholesterolemia · United States2CompletedEsperion TherapeuticsJun 1, 201763
NCT03001076Hypercholesterolemia · United States3CompletedEsperion TherapeuticsJan 11, 2018269
NCT02993406Cardiovascular Diseases · United States, Argentina, Australia and more3CompletedEsperion TherapeuticsNov 7, 202213,970
NCT02991118Hypercholesterolemia · United States3CompletedEsperion TherapeuticsAug 22, 2018779
NCT02988115Hypercholesterolemia · United States, Canada3CompletedEsperion TherapeuticsMar 16, 2018345
NCT02666664Hypercholesterolemia · United States, Canada, Germany and more3CompletedEsperion TherapeuticsFeb 21, 20182,230
NCT02659397Hyperlipidemias · United States2CompletedEsperion TherapeuticsJul 201668
NCT02178098Hypercholesterolemia · United States2CompletedEsperion TherapeuticsMay 22, 2015143
NCT02072161Hypercholesterolemia · United States2CompletedEsperion TherapeuticsJan 2015133
NCT01941836Hypercholesterolemia · United States2CompletedEsperion TherapeuticsOct 2014349
NCT01779453Hypercholesterolemia · United States2CompletedEsperion TherapeuticsAug 201358
NCT01751984Hypercholesterolemia · United States2CompletedEsperion TherapeuticsMay 1, 201356
NCT01607294Hyperlipidemias · United States2CompletedEsperion TherapeuticsOct 201260
NCT01485146Safety Evaluation of Escalating Doses · United States1CompletedEsperion TherapeuticsJan 25, 201224
NCT01262638Dyslipidemias · United States2CompletedEsperion TherapeuticsAug 23, 2011177

How it is read

Names in the registry

  • “ETC-1002”, 10 entries
  • “Bempedoic acid”, 7 entries
  • “180mg of ETC-1002(bempedoic acid)”, 3 entries
  • “bempedoic acid”, 3 entries
  • “Bempedoic Acid Tablet”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.